Management of metabolic-associated fatty liver disease: The diabetology perspective

Jeeyavudeen, Mohammad Sadiq; Khan, Shahanas KA; Fouda, Sherouk; Pappachan, Joseph M

doi:10.3748/wjg.v29.i1.126

Cited by 22 publications

(20 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In early 2020, an international expert group introduced the metabolic dysfunction-associated fatty liver disease (MAFLD) definition, which offers a more inclusive approach than NAFLD. MAFLD identifies a broader range of patients with hepatic steatosis and high risks of metabolic disorders, including diverse causes of liver steatosis[ 11 , 12 ]. Additionally, metabolic dysfunction-associated steatohepatitis (MASH) involves liver inflammation in the diagnosis[ 13 ].…”

Section: Search Resultsmentioning

confidence: 99%

From liver to hormones: The endocrine consequences of cirrhosis

Quiroz-Aldave,

Gamarra-Osorio,

Durand-Vásquez

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

Hepatocrinology explores the intricate relationship between liver function and the endocrine system. Chronic liver diseases such as liver cirrhosis can cause endocrine disorders due to toxin accumulation and protein synthesis disruption. Despite its importance, assessing endocrine issues in cirrhotic patients is frequently neglected. This article provides a comprehensive review of the epidemiology, pathophysiology, diagnosis, and treatment of endocrine disturbances in liver cirrhosis. The review was conducted using the PubMed/Medline, EMBASE, and Scielo databases, encompassing 172 articles. Liver cirrhosis is associated with endocrine disturbances, including diabetes, hypoglycemia, sarcopenia, thyroid dysfunction, hypogonadotropic hypogonadism, bone disease, adrenal insufficiency, growth hormone dysfunction, and secondary hyperaldosteronism. The optimal tools for diagnosing diabetes and detecting hypoglycemia are the oral glucose tolerance test and continuous glucose monitoring system, respectively. Sarcopenia can be assessed through imaging and functional tests, while other endocrine disorders are evaluated using hormonal assays and imaging studies. Treatment options include metformin, glucagon-like peptide-1 analogs, sodium-glucose co-transporter-2 inhibitors, and insulin, which are effective and safe for diabetes control. Established standards are followed for managing hypoglycemia, and hormone replacement therapy is often necessary for other endocrine dysfunctions. Liver transplantation can address some of these problems.

show abstract

Section: Search Resultsmentioning

confidence: 99%

From liver to hormones: The endocrine consequences of cirrhosis

Quiroz-Aldave,

Gamarra-Osorio,

Durand-Vásquez

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“… 183 Given the same Pathobiology of T2DM and MAFLD, both conditions coexist in many patients and may worsen the outcomes of underlying diseases with accelerated development and higher comorbidities. 184 …”

Section: Mafld and T2dmmentioning

confidence: 99%

Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment

Ding,

Deng,

Yang

et al. 2023

DMSO

View full text Add to dashboard Cite

Obesity,and metabolic dysfunction-associated fatty liver disease (MAFLD) have reached epidemic proportions globally. Obesity and MAFLD frequently coexist and act synergistically to increase the risk of adverse clinical outcomes (both hepatic and extrahepatic). Type 2 diabetes mellitus (T2DM) is the most important risk factor for rapid progression of steatohepatitis and advanced fibrosis. Conversely, the later stages of MAFLD are associated with an increased risk of T2DM incident. According to the proposed criteria, MAFLD is diagnosed in patients with liver steatosis and in at least one in three: overweight or obese, T2DM, or signs of metabolic dysregulation if they are of normal weight. However, the clinical classification and correlation between obesity and MAFLD is more complex than expected. In addition, treatment for obesity and MAFLD are associated with a reduced risk of T2DM, suggesting that liver-based treatments could reduce the risk of developing T2DM. This review describes the clinical classification of obesity and MAFLD, discusses the clinical features of various types of obesity and MAFLD, emphasizes the role of visceral obesity and insulin resistance (IR) in the development of MAFLD,and summarizes the existing treatments for obesity and MAFLD that reduce the risk of developing T2DM.

show abstract

“…Non-alcoholic fatty liver disease, also known as metabolicassociated fatty liver disease (MAFLD), is dened by the abnormal concentrations of triglycerides and other lipids in liver cells. 1,2 This prevalent ailment can advance from basic fatty liver to inammation of the liver known as steatohepatitis, and ultimately result in severe liver disorders. 3 MAFLD is strongly associated with disruptions in overall energy metabolism, such as insulin resistance and atherogenic dyslipidemia.…”

Section: Introductionmentioning

confidence: 99%